Fulvestrant (‘Faslodex’): Clinical experience from the Compassionate Use Programme
- 31 December 2005
- journal article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 31, S10-S16
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrantBreast Cancer Research and Treatment, 2005
- Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized TrialJournal of Clinical Oncology, 2004
- Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal womenCancer, 2003
- Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trialsEuropean Journal of Cancer, 2003
- Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine TherapyBreast Cancer Research and Treatment, 2003
- Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American TrialJournal of Clinical Oncology, 2002
- Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine TreatmentJournal of Clinical Oncology, 2002
- Similarities and distinctions in the mode of action of different classes of antioestrogens.Endocrine-Related Cancer, 2000
- Use of pure antioestrogens to elucidate the mode of action of oestrogensBiochemical Pharmacology, 1995